QuartzBio's platform is designed to address challenges in clinical development operations.

QuartzBio, a life science technology company delivering portfolio‑scale sample and biomarker intelligence for clinical‑stage biopharma, today announced a strategic growth investment and controlling ...

LAUSANNE, Switzerland -- Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs ...

QuartzBio provides a vendor-agnostic software platform that helps biopharma companies manage biospecimens and biomarker data across clinical trial portfolios.

The SIB Swiss Institute of Bioinformatics, Geneva Bioinformatics (GeneBio) SA and Quartz Bio SA today announced the establishment of a long-term collaboration under which they will cooperate in order ...

Eir Partners has made a growth investment in QuartzBio, a Frederick, Maryland-based life science technology company. No ...

Quartz Bio will offer highly specialized services to the pharmaceutical industry in the field of biomarker data analysis Merck Serono, a division of Merck, Darmstadt, Germany, announced today the ...

Merck Serono, the biopharmaceutical division of Merck KGaA ( MKGAF), announced the creation of a new company, Asceneuron. Asceneuron is the third spin-off company of Merck Serono, apart from Prexton ...

Discussing the platform and M&A opportunities firms see in the pharmaceutical and life science sector; a look at Eir Partners ...

Debiopharm Group™ has announced that they have signed a one-year collaboration agreement with Quartz Bio, the Clinical Bioinformatics Research Organization leader in precision biomarker discovery.

Merck Serono, a division of Merck, Darmstadt, Germany, announced today the creation of Quartz Bio, the second spin-off company resulting from its Entrepreneur Partnership Program launched in April ...